Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, discusses Lung-MAP studies in which a higher tumor mutation burden determined by next-generation sequencing was linked to overall and progression-free survival across two immunotherapy trials, and was independent of PD-L1 status (Abstract OA01.04).
Prasad S. Adusumilli, MD, of Memorial Sloan Kettering Cancer Center, discusses ongoing CAR T-cell therapy clinical trials for solid tumors, the key determinants of success fo...
Martin Reck, MD, PhD, of the LungenClinic, discusses findings of the KEYNOTE-598 study, which showed that pembrolizumab plus ipilimumab was more toxic and offered no more ben...
Jill Feldman, a patient advocate who has lost five family members to lung cancer and is herself a 12-year cancer survivor living with EGFR-positive disease, describe...
Justin F. Gainor, MD, of Massachusetts General Hospital, discusses two key phase II studies on non–small cell lung cancer: nivolumab vs nivolumab plus ipilimumab in EGFR<...
